Bionano Genomics Announces the First Publication Using OGM to Analyze Impact of Chromothripsis and TP53 Abnormalities on Chronic Lymphocytic Leukemia (CLL) Patients with High Genomic Complexity
August 25 2022 - 8:00AM
Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the
publication of the first study to use optical genome mapping (OGM)
to analyze the impact of chromothripsis (cth) and TP53
abnormalities on chronic lymphocytic leukemia (CLL) patients with
high genomic complexity. Researchers aimed to determine whether
poor prognostic outcomes observed in cases with cth might be
related not only to the chromothriptic event itself but also to the
presence of complex karyotypes or TP53 abnormalities.
The paper, published in Cancers journal, was conducted by a
multi-center group of researchers from hospitals and academic labs
across a number of European countries. The study compared the
cytogenomic aberrations observed by genomic microarrays and
chromosome banding analysis (CBA) to those observed using OGM.
Researchers analyzed a cohort of 162 CLL patients with complex
karyotypes, including a subset of 33 CLL patients with cth, to
determine whether the presence of cth indicated poor survival
outcomes.
In this study, researchers were able to show, for the first
time, OGM’s ability to detect cth, and also showed that the OGM
results were highly concordant with chromosomal microarray results.
The study noted that detecting cth using some traditional
cytogenetic approaches can be challenging and reported that OGM was
able to reveal rearrangements associated with cth events, including
intra-chromosomal and inter-chromosomal translocations. In
addition, OGM was able to detect a case with a higher complexity
profile, comprising chained translocations involving several
chromosomes, which may be characteristic of another event known as
chromoplexy.
Though cases with cth showed shorter time to first treatment
(TTFT) than non-cth samples, when researchers stratified patients
based on TP53 status, cth was no longer associated with TTFT. Only
TP53 maintained its significance in the multivariate analysis for
TTFT, including cth and genome complexity defined by genomic
microarrays, leading the researchers to suggest that TP53
abnormalities, rather than cth itself, underlie the poor prognosis
observed in this subset.
“We are excited to see the adoption of OGM in the hematologic
community in Spain. This team of researchers have done outstanding
work diving into some complex questions in cancer. The results of
this study show that while chromothripsis plays a factor in the
proliferation of structural variation, TP53 emerges as a critical
biomarker with high prognostic value. We believe the study also
shows that OGM was unique in its potential to reveal these critical
events. The report shows that a few of the variants detected by CMA
were not detected by OGM, which we believe reflects the performance
of earlier versions of our analysis software and will help guide
development of future versions. It is noteworthy that this
publication documents OGM’s ability to analyze TP53 variants,
because we are aware of new international classification subtypes
that emphasize the importance of TP53 structural variants in
conjunction with single nucleotide variants,” commented Erik
Holmlin, PhD, president and chief executive officer of Bionano
Genomics.
This publication can be found here:
https://www.mdpi.com/2072-6694/14/15/3715
About Bionano Genomics
Bionano Genomics is a provider of genome analysis solutions that
can enable researchers and clinicians to reveal answers to
challenging questions in biology and medicine. The Company’s
mission is to transform the way the world sees the genome through
OGM solutions, diagnostic services and software. The Company offers
OGM solutions for applications across basic, translational and
clinical research. Through its Lineagen business, the Company also
provides diagnostic testing for patients with clinical
presentations consistent with autism spectrum disorder and other
neurodevelopmental disabilities. Through its BioDiscovery business,
the Company also offers an industry-leading, platform-agnostic
software solution, which integrates next-generation sequencing and
microarray data designed to provide analysis, visualization,
interpretation and reporting of copy number variants, single
nucleotide variants and absence of heterozygosity across the genome
in one consolidated view.
For more information, visit www.bionanogenomics.com,
www.lineagen.com or www.biodiscovery.com
Forward-Looking Statements of Bionano
GenomicsThis press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Words such as “believe,” “potential,” and
similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) convey
uncertainty of future events or outcomes and are intended to
identify these forward-looking statements. Forward-looking
statements include statements regarding our intentions, beliefs,
projections, outlook, analyses or current expectations concerning,
among other things, the ability and utility of OGM to analyze
chromothripsis (cth) and TP53 abnormalities on chronic lymphocytic
leukemia (CLL) patients with high genomic complexity. Each of these
forward-looking statements involves risks and uncertainties. Actual
results or developments may differ materially from those projected
or implied in these forward-looking statements. Factors that may
cause such a difference include the risks and uncertainties
associated with: the impact of the COVID-19 pandemic on our
business and the global economy; general market conditions; changes
in the competitive landscape and the introduction of competitive
technologies or improvements to existing technologies; failure of
OGM to achieve utility in the analysis of chromothripsis (cth) and
TP53 abnormalities on chronic lymphocytic leukemia (CLL) patients
with high genomic complexity; failure of future study results to
support those demonstrated in the paper referenced in this press
release; changes in our strategic and commercial plans; our ability
to obtain sufficient financing to fund our strategic plans and
commercialization efforts; the ability of medical and research
institutions to obtain funding to support adoption or continued use
of our technologies; and the risks and uncertainties associated
with our business and financial condition in general, including the
risks and uncertainties described in our filings with the
Securities and Exchange Commission, including, without limitation,
our Annual Report on Form 10-K for the year ended December 31, 2021
and in other filings subsequently made by us with the Securities
and Exchange Commission. All forward-looking statements contained
in this press release speak only as of the date on which they were
made and are based on management’s assumptions and estimates as of
such date. We do not undertake any obligation to publicly update
any forward-looking statements, whether as a result of the receipt
of new information, the occurrence of future events or
otherwise.
CONTACTSCompany Contact:Erik
Holmlin, CEOBionano Genomics, Inc.+1 (858)
888-7610eholmlin@bionanogenomics.com
Investor Relations:Amy ConradJuniper Point+1
(858) 366-3243amy@juniper-point.com
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Apr 2023 to Apr 2024